Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Derivados de purinas para el tratamiento de enfermedades neurodegenerativas

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20170411001
Publicado:
09/06/2017
Caducidad:
09/06/2018
Resumen:
Un centro de investigación español ha sintetizado una serie de derivados de purina sustituidas que son capaces de inhibir la actividad de la quinasa CDC7 (ciclo de división celular 7). Esta actividad inhibitoria los hace útiles para el tratamiento de enfermedades neurológicas. Los compuestos desarrollados son una nueva alternativa terapéutica para la enfermedad de Alzheimer, esclerosis lateral amiotrófica o demencia frontotemporal. Las moléculas son capaces de atravesar la barrera hematoencefálica, propiedad esencial para cualquier fármaco que deba actuar en el sistema nervioso central. El centro de investigación busca empresas farmacéuticas con el fin de establecer acuerdos de licencia.

Details

Tittle:
Purine derivatives for the treatment of neurodegenerative diseases
Summary:
A Spanish Research Public Organization has synthesized several substituted purine derivatives that are capable of inhibiting the activity of the CDC7 (Cell division cycle 7) kinase. This inhibitory activity makes them useful for the treatment of neurological diseases. The compounds developed are a new therapeutic alternative for Alzheimer´s disease, amyotrophic lateral sclerosis or frontotemporal dementia. Industrial partners from pharmaceutical industry are being sought for a license agreement.
Description:
Nowadays, there is no effective treatment against neurodegenerative diseases, so finding new molecules that can be used as drugs is a priority objective in the research on these pathologies.
The hyperphosphorylation of the protein TDP-43 induces the formation of aggregates that have been detected in patients with amyotrophic lateral sclerosis or with frontotemporal lobular degeneration. It has been found that CDC7 kinase is responsible for the dual hyperphosphorylation of TDP-43 in 409/410 serines in certain models, so inhibition of this CDC7 kinase would be an interesting strategy to develop drugs for neurodegenerative diseases.
The new synthesized compounds, purine derivatives, are CDC-7 inhibitors and useful as potential drugs for diseases mediated by TDP-43 proteinopathies, such as Alzheimer´s disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia

The Spanish research centre is searching for a Company interested in the developement and commerzialization of this novel compunds under a license agreement. The compounds have only been tested at a laboratory scale, therefore some further development might be need and the Spanish research centre could collaborate with the company in that project.

The Spanish research centre has a broad experience in developing novel compounds to be tested as potential candidates to treat neurodegenerative patologies.
Advantages and Innovations:
They are able to cross the blood brain barrier to exert its pharmacological action , an essential property for any drug that must act in the central nervous system.

Constitute a solid and innovative alternative in the search for treatments for neurodegenerative diseases.

They can be presented in the most suitable pharmaceutical formulation for each treatment.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Spanish patent application

Partner sought

Type and Role of Partner Sought:
Industrial partners from pharmaceutical industry are being sought to develop and commercialized the compounds through a patent licence agreement.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos